Japanese Dental Startup Toregem Raises $5.3 M to Treat Congenital Tooth Agenesis.

Japan-based startup Toregem BioPharma is in a Pre-Series C financing round, allocating J-KISS-type stock acquisition rights to a new investor and also conducting a third-party allotment of new shares with subscribing companies, including JIC Venture Growth Investments (VGI).

With this Pre-Series C funding, Toregem will conduct Phase II clinical trials of TRG035, a humanised anti-USAG-1 antibody, in Japan, and is being prepared for future clinical development in the United States, and will further accelerate the clinical development. Its cumulative funding, including grants and subsidies, has exceeded $29 million.

According to Towards Healthcare, the Japan oral care market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 4.22 billion in 2026 to approximately USD 7.07 billion by 2035, representing a compound annual growth rate (CAGR) of 5.92% from 2026 to 2035. Growth is driven by a focus on preserving their natural teeth and preventing age-related oral diseases, and these consumers exhibit a strong preference for preventive care over curative treatments. This cultural shift has spurred the widespread adoption of medical-grade and preventive oral care products rather than just basic hygiene items.

About TRG-035

TRG-035 represents a massive shift for the Japanese oral care market, offering a biological alternative to traditional dentures, bridges, and titanium implants. Rather than managing hardware, patients could naturally regrow functional teeth. It is administered in the form of an intravenous injection to ensure it reaches the systemic circulation quickly and carries out the intended biological process.

It targets a protein called USAG-1, which acts as a natural blocker of tooth development in the human body. Scientists discovered that USAG-1 suppresses the activity of bone morphogenetic protein (BMP), a molecule that plays an important role in tooth formation.

Researchers are aiming for a public commercial release by 2030, presenting a non-invasive biological alternative to traditional mechanical solutions like dentures, bridges, and metal implants. A shift from implants and dentures to a natural teeth regeneration process by a dentist might be seen, enhancing patient outcomes and satisfaction.
A recent report by Towards Healthcare highlights that the Japan oral care market is witnessing growth due to high national health awareness; shoppers heavily favor products that offer eco-friendly packaging, holistic health integration, and proven technological superiority; an aging demographic; a strong cultural emphasis on preventive healthcare; and a high demand for premium, specialized therapeutic and cosmetic products.